Bristol Myers Squibb buys Nvidia AI system for drug discovery

Bristol Myers Squibb is purchasing an Nvidia DGX SuperPOD built on the Vera Rubin architecture to support AI in drug discovery. The pharmaceutical company will be the first life sciences group to acquire this system. Nvidia introduced the Vera Rubin architecture earlier this year. The deal aims to accelerate drug development through advanced AI computing.